Candel Therapeutics (CADL) Shares Outstanding (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Shares Outstanding (Entity) data on file, last reported at $55.0 million in Q4 2025.

• For the quarter ending Q4 2025, Shares Outstanding (Entity) rose 73.7% year-over-year to $55.0 million; the trailing twelve-month figure through Dec 2025 stood at $55.0 million (up 73.7% YoY), and the FY2025 full-year result was $55.0 million, up 73.7% from the prior year.
• Shares Outstanding (Entity) held at $55.0 million in Q4 2025, from $55.0 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $55.0 million in Q4 2025 to a low of $11.6 million in Q1 2021.
• A 5-year average of $31.8 million and a median of $29.0 million in 2022 frame the typical range for Shares Outstanding (Entity).
• Across the five-year window, Shares Outstanding (Entity) jumped 147.31% in 2022 and advanced 0.1% in 2023, its largest moves.
• Tracing CADL's Shares Outstanding (Entity) over 5 years: stood at $18.9 million in 2021, then soared by 53.88% to $29.0 million in 2022, then gained by 0.59% to $29.2 million in 2023, then gained by 8.43% to $31.7 million in 2024, then soared by 73.7% to $55.0 million in 2025.
• Business Quant data shows CADL's Shares Outstanding (Entity) at $55.0 million in Q4 2025, $55.0 million in Q3 2025, and $55.0 million in Q2 2025.